--- title: "Taysha Gene Therapies | 8-K: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/285375211.md" datetime: "2026-05-06T12:15:25.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285375211.md) - [en](https://longbridge.com/en/news/285375211.md) - [zh-HK](https://longbridge.com/zh-HK/news/285375211.md) --- # Taysha Gene Therapies | 8-K: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.12, missing the estimate of USD -0.0958. EBIT: As of FY2026 Q1, the actual value is USD -46.06 M. #### First Quarter 2026 Financial Highlights #### Revenue For the three months ended March 31, 2026, revenue was $0 . For the three months ended March 31, 2025, revenue was $2,302 thousand . #### Research and Development Expenses Research and Development Expenses were $33,809 thousand for the three months ended March 31, 2026, compared to $15,565 thousand for the three months ended March 31, 2025 . The $18,244 thousand increase was primarily due to BLA-enabling PPQ manufacturing initiatives and higher clinical expenses from the REVEAL and ASPIRE trials, as well as increased compensation expenses . #### General and Administrative Expenses General and Administrative Expenses were $9,677 thousand for the three months ended March 31, 2026, compared to $8,158 thousand for the three months ended March 31, 2025 . The $1,519 thousand increase was mainly due to higher compensation expenses and increases in consulting and professional fees, including commercial launch-readiness initiatives . #### Total Operating Expenses Total Operating Expenses were $43,486 thousand for the three months ended March 31, 2026, compared to $23,723 thousand for the three months ended March 31, 2025 . #### Net Loss Net loss for the three months ended March 31, 2026, was - $42,410 thousand, or - $0.12 per share . This compares to a net loss of - $21,529 thousand, or - $0.08 per share, for the three months ended March 31, 2025 . #### Cash and Cash Equivalents As of March 31, 2026, Taysha Gene Therapies, Inc. had $276,576 thousand in cash and cash equivalents . As of December 31, 2025, cash and cash equivalents were $319,767 thousand . #### Total Assets As of March 31, 2026, total assets were $300,351 thousand . As of December 31, 2025, total assets were $343,320 thousand . #### Total Liabilities As of March 31, 2026, total liabilities were $88,407 thousand . As of December 31, 2025, total liabilities were $96,382 thousand . #### Total Stockholders’ Equity As of March 31, 2026, total stockholders’ equity was $211,944 thousand . As of December 31, 2025, total stockholders’ equity was $246,938 thousand . #### Recent Corporate and TSHA-102 Program Highlights Taysha Gene Therapies, Inc. reaffirmed FDA alignment on the planned BLA submission pathway for TSHA-102, including pivotal trial design, endpoints, and the potential for approval based on the six-month interim analysis from the REVEAL pivotal trial . Dosing in the REVEAL pivotal trial has further advanced across multiple sites, and enrollment in the ASPIRE trial is ongoing across multiple sites . TSHA-102 continues to be generally well tolerated, with no treatment-related serious adverse events (SAEs) or dose-limiting toxicities (DLTs) observed in patients treated in the REVEAL Phase 1⁄2 and REVEAL pivotal trials as of the May 2026 data cutoff . The company initiated the BLA-enabling Process Performance Qualification (PPQ) campaign for TSHA-102 using the commercial manufacturing process in April 2026, following FDA endorsement of the strategy . A peer-reviewed publication on April 28, 2026, further validated lumbar intrathecal (IT) dosing as a safe and effective approach for gene therapy delivery to the CNS, demonstrating comparable biodistribution of AAV9 vector in non-human primates . An abstract highlighting new preclinical in vitro data for TSHA-102 was accepted for presentation at the ASGCT 2026 Annual Meeting on May 14, 2026 . #### Outlook / Guidance Taysha Gene Therapies, Inc. anticipates completing dosing in both the REVEAL pivotal trial and ASPIRE trial in the second quarter of 2026, with an update on longer-term safety and efficacy data from Part A of the REVEAL Phase 1⁄2 trials also expected in the same quarter . The BLA-enabling PPQ campaign for TSHA-102 is projected to be completed in the fourth quarter of 2026 . The company expects its current cash and cash equivalents to fund planned operating expenses into 2028 . ### Related Stocks - [TSHA.US](https://longbridge.com/en/quote/TSHA.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Americold declares USD 0.23 per share Q2 2026 dividend](https://longbridge.com/en/news/287268362.md) - [Endeavour Announces Results of Annual General Meeting 2026 | EDVMF Stock News](https://longbridge.com/en/news/287245296.md)